![]() | |
Clinical data | |
---|---|
Trade names | Veozah, Veoza |
Other names | ESN-364 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a623051 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 51%[6][unreliable medical source?] |
Metabolism | CYP1A2, (CYP2C9, CYP2C19 to lesser extent)[3] |
Metabolites | ES259564[7] |
Elimination half-life | 9.6h[3] |
Excretion | Urine 76.9%, feces 14.7%[8][unreliable medical source?] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H15FN6OS |
Molar mass | 358.40 g·mol−1 |
3D model (JSmol) | |
| |
|
Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause.[3][9] It is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which is under development by for the treatment of sex hormone-related disorders.[medical citation needed] It is taken by mouth.[3] It is developed by Astellas Pharma which acquired it from Ogeda (formerly Euroscreen) in April 2017.[10][11][12]
The most common side effects include abdominal pain, diarrhea, insomnia, back pain, hot flush and elevated hepatic transaminases.[9]
Fezolinetant was approved for medical use in the United States in May 2023,[9] and in the European Union in December 2023.[4][5] Fezolinetant is the first neurokinin 3 (NK3) receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause.[9] The FDA considers it to be a first-in-class medication.[13]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search